Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates
Information source: University of Connecticut Health Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psychosis; Aggression
Intervention: risperidone (Drug)
Phase: N/A
Status: Terminated
Sponsored by: University of Connecticut Official(s) and/or principal investigator(s):
catherine f lewis, md, Principal Investigator, Affiliation: University of Connecticut Health Center
Summary
This study examines the efficacy of haldol versus risperdal in the treatment of aggression
in psychotic prison inmates. It is hypothsized that risperdal will be more effective in
decreasing aggression than haldol.
Clinical Details
Official title: Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria: age 18 or over, psychotic disorder diagnosed on SCID, inmate at
correctional facility for at least 2 weeks -
Exclusion Criteria: active withdrawal from substances of abuse, non-psychotic
individuals, pregnant women, people unable to give informed consent, patients on mood
stabilizers
-
Locations and Contacts
University of connecticut health center, Farmington, Connecticut 06030, United States
Additional Information
Starting date: July 2002
Last updated: October 12, 2006
|
